SEC Form SC 13G filed by INmune Bio Inc.

$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $INMB alert in real time by email
SC 13G 1 inmb-sc13g_071421.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

 
INmune Bio, Inc.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
45782T105
(CUSIP Number)
 
July 14, 2021
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

  Rule 13d-1(b)
     
  Rule 13d-1(c)
     
  Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
Page 2 of 9

 

CUSIP No.    45782T105    

 

  

1

NAME OF REPORTING PERSONS
Altium Capital Management, LP

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY) EIN: 82-2066653

 
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3 SEC USE ONLY  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware, United States of America

 

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH
REPORTING

PERSON
WITH:

5

SOLE VOTING

0

 
6

SHARED VOTING POWER

909,091 shares of Common Stock

 
7

SOLE DISPOSITIVE POWER

0

 
8

SHARED DISPOSITIVE POWER

909,091 shares of Common Stock

 
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

909,091 shares of Common Stock

 
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.1%(1)

 
12

TYPE OF REPORTING PERSON

IA, PN

 
         

(1)Based on 17,658,692 shares of Common Stock outstanding as of July 14, 2021 as set forth in the Issuer’s Form 424B5 filed with the Securities and Exchange Commission on July 15, 2021.

 

 
Page 3 of 9

  

CUSIP No. 45782T105    

 

 

1

NAME OF REPORTING PERSONS
Altium Growth Fund, LP

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY) EIN: 82-2105101

 
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b) x

3 SEC USE ONLY  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware, United States of America

 

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH
REPORTING

PERSON
WITH:

5

SOLE VOTING

0

 
6

SHARED VOTING POWER

909,091 shares of Common Stock

 
7

SOLE DISPOSITIVE POWER

0

 
8

SHARED DISPOSITIVE POWER

909,091 shares of Common Stock

 
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

909,091 shares of Common Stock

 
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.1%(1)

 
12

TYPE OF REPORTING PERSON

PN

 
         

(1)Based on 17,658,692 shares of Common Stock outstanding as of July 14, 2021 as set forth in the Issuer’s Form 424B5 filed with the Securities and Exchange Commission on July 15, 2021.

 

 
Page 4 of 9

  

CUSIP No. 45782T105    

 

 

1

NAME OF REPORTING PERSONS
Altium Growth GP, LLC

 

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY) EIN: 82-2086430

 
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3 SEC USE ONLY  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware, United States of America

 

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH
REPORTING

PERSON
WITH:

5

SOLE VOTING

0

 
6

SHARED VOTING POWER

909,091 shares of Common Stock

 
7

SOLE DISPOSITIVE POWER

0

 
8

SHARED DISPOSITIVE POWER

909,091 shares of Common Stock

 
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

909,091 shares of Common Stock

 
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.1%(1)

 
12

TYPE OF REPORTING PERSON

OO

 
         

(1)Based on 17,658,692 shares of Common Stock outstanding as of July 14, 2021 as set forth in the Issuer’s Form 424B5 filed with the Securities and Exchange Commission on July 15, 2021.

 

 
Page 5 of 9

 

CUSIP No. 45782T105    

 

  

Item 1(a).   Name of Issuer: INmune Bio, Inc. (the “Issuer”)
     
Item 1(b).   Address of Issuer’s Principal Executive Offices: 980 North Federal Highway, Suite 110
Boca Raton, FL 33432
     
Item 2(a).  

Name of Person Filing:

This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

 

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

 

Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     
Item 2(b).   Address of Principal Business Office or, if None, Residence:
    The address of the principal business office of each of the reporting persons is
152 West 57th Street, FL 20, New York, NY 10019
     
Item 2(c).   Citizenship:
    See Item 4 on the cover page(s) hereto.
     
Item 2(d).   Title of Class of Securities:
    Common Stock, par value $0.001 per shares (“Common Stock”)
     
Item 2(e).   CUSIP Number: 45782T105
     
Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

   
  (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
       
  (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

 

 
Page 6 of 9

 

CUSIP No. 45782T105    

 

 

  (c)

Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

       
  (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       
  (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
       
  (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
       
  (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).
       
Item 4. Ownership.
 

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 17,658,692 shares of Common Stock outstanding as of July 14, 2021 as set forth in the Issuer’s Form 424B5 filed with the Securities and Exchange Commission on July 15, 2021.

 

 

 

 
Page 7 of 9

 

CUSIP No . 45782T105    

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
  Not applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
  Not applicable
   
Item 8. Identification and Classification of Members of the Group.
  Not applicable
   
Item 9. Notice of Dissolution of Group.
  Not applicable
   
Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 16, 2021
   
  Altium Capital Management, LP
   
  By: /s/ Jacob Gottlieb
  Name: Jacob Gottlieb
  Title: CEO
     
  Altium Growth Fund, LP
     
  By: Altium Growth GP, LLC
  Its: General Partner
     
Signature: /s/ Jacob Gottlieb
Name: Jacob Gottlieb
Title: Managing Member of Altium Growth GP, LLC
   
  Altium Growth GP, LLC
 
By: /s/ Jacob Gottlieb
  Jacob Gottlieb
  Managing Member

 

 
Page 8 of 9

 

EXHIBIT INDEX

 

EXHIBIT 1 Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
   
  Members of Group

 

 

 
Page 9 of 9

 

 

EXHIBIT 1

 

JOINT ACQUISITION STATEMENT

PURSUANT TO SECTION 240.13d-1(k)

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

 

Dated: July 16, 2021
   
  Altium Capital Management, LP
   
  By: /s/ Jacob Gottlieb
  Name: Jacob Gottlieb
  Title: CEO
     
  Altium Growth Fund, LP
     
  By: Altium Growth GP, LLC
  Its: General Partner
     
Signature: /s/ Jacob Gottlieb
Name: Jacob Gottlieb
Title: Managing Member of Altium Growth GP, LLC
   
  Altium Growth GP, LLC
 
By: /s/ Jacob Gottlieb
  Jacob Gottlieb
  Managing Member

 

 

 

 

Get the next $INMB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INMB

DatePrice TargetRatingAnalyst
1/28/2025$23.00Buy
Rodman & Renshaw
10/21/2024$20.00Buy
Alliance Global Partners
9/27/2024$18.00Outperform
Raymond James
8/22/2024$22.00Sector Outperform
Scotiabank
6/1/2023$16.00Outperform
Robert W. Baird
5/24/2022$14.00 → $7.00Buy → Neutral
B. Riley Securities
1/24/2022$32.00 → $20.00Buy
B. Riley Securities
7/7/2021$32.00 → $42.00Buy
Maxim Group
More analyst ratings

$INMB
Press Releases

Fastest customizable press release news feed in the world

See more
  • INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

    BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

    Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

    Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the "CaRe PC" trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort. The Scientific Review Committee (SRC) charter is to re

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$INMB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$INMB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$INMB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$INMB
SEC Filings

See more

$INMB
Leadership Updates

Live Leadership Updates

See more
  • INmune Bio Inc. to Join Russell 3000® Index

    Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

    DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$INMB
Financials

Live finance-specific insights

See more
  • INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

    BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. Full Year 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro1595, XPro™): Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early Alzheimer's Disease (AD) and biomarkers of elevated n

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

    Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator. Date: March 27, 2025 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 or 1-203-518-9708 Conference ID: INMUNE A li

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

    BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$INMB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$INMB
Insider purchases explained

Analytical look into recent insider purchases

See more
  • Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care